Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Marshall on the Role of Fruquintinib in the Treatment Paradigm for mCRC

August 20th 2025

John L. Marshall, MD, discusses the use of fruquintinib in the treatment of patients with metastatic colorectal cancer.

Fruquintinib Efficacy Data Support Its Use in the Third-Line Advanced CRC Setting

August 20th 2025

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

FDA Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

August 20th 2025

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Magrolimab/Nivolumab Combos Drive Responses in Unresectable Advanced/Recurrent CRC

August 19th 2025

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

Dr García-Carbonero on Outcomes With Fruquintinib in mCRC Subgroups

August 15th 2025

Rocío García-Carbonero, MD, discusses fruquintinib for the treatment of patients with metastatic colorectal cancer.

Ongoing Research Prompts Key Sequencing Considerations in CRC, Pancreatic Cancer

August 11th 2025

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Fulzerasib Displays Efficacy and Tolerability in KRAS G12C–Mutated Metastatic CRC

August 11th 2025

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

Dr Eng on the Future Role for Targeted Therapy in mCRC

August 7th 2025

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Botensilimab Plus Balstilimab Shows Durable Activity in Refractory CRC Across Lines of Therapy

August 7th 2025

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Rising Early‑Onset CRC Rates in Asia Underscore Global Trend in Incidence and Need for Coordinated Research Efforts

August 6th 2025

Evelyn Y. Wong, MD, discusses an analysis of a multiracial Asian cohort on the incidence of early‑onset colorectal cancer.

Dr Wong on Survival Outcomes and Molecular Characteristics of Patients with Early-Onset CRC

August 5th 2025

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Neoadjuvant Pembrolizumab Could Represent Avenue for Organ Preservation in Nonmetastatic, Unresectable dMMR CRC

August 5th 2025

Neoadjuvant pembrolizumab could represent an avenue for organ preservation in nonmetastatic, unresectable, dMMR colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Dr Sinicrope on the Clinical Implications of the ATOMIC Trial for Stage III dMMR CRC

July 31st 2025

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Revisit Every OncLive On Air Episode From July 2025

July 31st 2025

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

First-Line Onvansertib Plus Bevacizumab and Chemo Yields Responses in RAS-Mutated mCRC

July 30th 2025

Onvansertib plus SOC generated responses with a tolerable safety profile in patients with previously untreated RAS-mutated metastatic colorectal cancer.

Experts Weigh In on the Treatment of mCRC

July 30th 2025

Panelists discuss how important clinical pearls include early genomic profiling, emphasizing lifestyle modifications like exercise programs that can reduce recurrence by 7%, and using olanzapine as the most effective antiemetic for delayed chemotherapy-related nausea.

Expert Perspectives on Balancing Therapy Decisions and Quality of Life in mCRC

July 30th 2025

Panelists discuss how immunotherapy generally provides better quality of life compared to traditional chemotherapy, particularly noting that microsatellite instability-high patients on immune checkpoint inhibitors report significantly better experiences than those on FOLFOX regimens.

Quality of Life Assessment Tools In mCRC

July 23rd 2025

Panelists discuss how they assess quality of life in clinical practice by asking simple questions like “What do you do for fun?” and “How was your week?” rather than relying solely on formal quality of life questionnaires.

Defining Clinically Meaningful Outcomes and Looking Ahead at Future Treatment Options for mCRC

July 23rd 2025

Panelists discuss how they’re excited about future combination therapies, particularly TAS-102 with fruquintinib and novel immunotherapy approaches targeting patients with liver metastases who are typically checkpoint inhibitor refractory.